PimedBio

  • ABOUT US
    About Us

    We create new treatments
    based on cutting-edge approaches.

    • STARTUP STORY
    • HISTORY
    • LEADERSHIP
    • PARTNERSHIP & COLLABORATION
    • LOCATION
  • PLATFORM
    Platform

    We create new treatments
    based on cutting-edge approaches.

    • Platform Technology
  • PIPELINE
    Pipeline

    We create new treatments
    based on cutting-edge approaches.

    • OVERVIEW
    • Oncology
    • IMMUNOLOGY
  • PR
    PR

    We create new treatments
    based on cutting-edge approaches.

    • News
    • Notice
    • IR
  • CAREER
    CAREER

    We create new treatments
    based on cutting-edge approaches.

    • Recruitment notice
    • Join us
EN
  • KR
  • About Us
    • Startup story
    • History
    • Leadership
    • Partnership & Collaboration
    • Location
  • Platform
    • Platform technology
  • Pipeline
    • Overview
    • Oncology
      • Inhibitor-drug conjugates: IDC
      • The 3rd-Generation Immuno-oncology therapeutics
    • Immunology
      • PMB702(Novel IBD therapeutics)
  • PR
    • News
    • Notice
    • IR
  • Creer
    • Recruitment notice
    • Join Us

PR

Based on innovative scientific achievements,
Pimedbio's first-in-class drugs
  • News
  • Notice
  • IR
  • home
  • PR
  • Notice

  • Notice
    2025.03.12
    제 8회 정기 주주총회
  • Notice
    2024.03.13
    제 7회 정기주주총회
  • Notice
    2023.12.19
    파이메드바이오_2023 국가신약개발사업 10대 우수과제 선정
  • Notice
    2023.10.26
    임시 주주총회 안내
  • Notice
    2023.03.14
    제6기 정기주주총회
  • Notice
    2022.03.15
    제5기 정기주주총회
  • Notice
    2022.02.08
    케이메디허브와 위탁생산 및 개발 관련 업무협약식(MOU)
  • Notice
    2022.02.07
    임시주주총회
1

2nd floor, H2233, Healthcare Innovation Park, Bundang Seoul National University Hospital, 172 Dolmaro, Bundang-gu, Seongnam-si, Gyeonggi-do
Tel. 031-8039-7240 Fax. 050-4001-4874
  • 개인정보처리방침
  • 이메일무단수집거부
Copyright(C) Pimedbio. All Rights Reseved.